Delving into the Latest Updates on Ichor Biologics LLC with Synapse

概览

关联

2

项与 Ichor Biologics LLC 相关的药物

JL-16

靶点

安第斯汉坦病毒糖蛋白

作用机制

安第斯汉坦病毒糖蛋白抑制剂

在研机构-

原研机构

Ichor Biologics LLC初创企业 [+1]

在研适应症-

非在研适应症

汉坦病毒感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

MIB-22

靶点

安第斯汉坦病毒糖蛋白

作用机制

安第斯汉坦病毒糖蛋白抑制剂

在研机构-

原研机构

Ichor Biologics LLC初创企业 [+1]

在研适应症-

非在研适应症

汉坦病毒感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Ichor Biologics LLC 相关的临床结果

登录后查看更多信息

0 项与 Ichor Biologics LLC 相关的专利（医药）

登录后查看更多信息

8

项与 Ichor Biologics LLC 相关的文献（医药）

2022-05-01·Cell Reports

IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes

Article

作者: Alvarez, Raymond A ; Bravo, Felipe ; Garrido, Jose L ; Bowman, James W ; Pinos, Yazmin ; Bahl, Christopher D ; Calvo, Mario ; McGee, Sarah ; Brachman, Rebecca A ; Barria, Maria Ines ; Medina, Matías A ; Fuentes-Villalobos, Francisco

Despite SARS-CoV-2 being a "novel" virus, early detection of anti-spike IgG in severe COVID-19 patients may be caused by the amplification of humoral memory responses against seasonal coronaviruses. Here, we examine this phenomenon by characterizing anti-spike IgG responses in non-hospitalized convalescent individuals across a spectrum of COVID-19 severity. We observe that disease severity positively correlates with anti-spike IgG levels, IgG cross-reactivity against other betacoronaviruses (β-CoVs), and FcγR activation. Analysis of IgG targeting β-CoV-conserved and non-conserved immunodominant epitopes within the SARS-CoV-2 spike protein revealed epitope-specific relationships: IgG targeting the conserved heptad repeat (HR) 2 region significantly correlates with milder disease, while targeting the conserved S2'FP region correlates with more severe disease. Furthermore, a lower HR2-to-S2'FP IgG-binding ratio correlates with greater disease severity, with ICU-hospitalized COVID-19 patients showing the lowest HR2/S2'FP ratios. These findings suggest that HR2/S2'FP IgG profiles may predict disease severity and offer insight into protective versus deleterious humoral recall responses.

2018-11-21·Science Translational Medicine1区 · 医学

Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo

1区 · 医学

Article

作者: Rioseco, Maria L. ; Barria, Maria I. ; Riquelme, Raul ; Prescott, Joseph ; Alvarez, Raymond ; Garrido, Jose L. ; Bravo, Felipe ; Feldmann, Heinz ; Haddock, Elaine ; Williamson, Brandi N. ; Calvo, Mario ; Salas, Alexis

Post-exposure highly potent human monoclonal antibodies target Andes hantavirus glycoprotein in a hamster hantavirus cardiopulmonary syndrome model.

Frontiers in Cellular and Infection Microbiology2区 · 医学

Differential CD4 T Regulatory Cell Phenotype Induced by Andes Hantavirus Glycoprotein

2区 · 医学

ArticleOA

作者: Garrido, Jose L ; Barria, Maria Ines ; Chahín, Carolina ; Riquelme, Raúl ; Alvarez, Raymond ; Saavedra, Farides ; Nova-Lamperti, Estefania ; Fuentes-Villalobos, Francisco ; Calvo, Mario ; Rioseco, María Luisa ; Ferreira, Leonila

Hantavirus cardiopulmonary syndrome (HCPS) caused by Andes orthohantavirus (ANDV) in South America is a public health threat due to the significant rate of mortality and the lack of a specific treatment. Interestingly, the virus does not produce cytopathic effect, thereby the strong antiviral immune response is suspected to contribute to pathogenesis, hence is important to understand the balance between protective and harmfully immunity. CD4⁺ T regulatory cells (Treg) are essential to control an exacerbated immune response. In human ANDV infection, little is known about CD4⁺ Treg cells, which may be involved in control immunopathology associated to the infection. In this report, we characterize the phenotype of memory CD4⁺ Tregs in a HCPS survivor's cohort. Based on the expression of CXCR3, CCR4, and CCR6, we identified different Th-like Treg populations in ANDV survival's PBMCs. In addition, the effect of ANDV-glycoprotein virus like particles (VLP) was determined. We demonstrated that memory CD4⁺ Treg from HCPS present a specific phenotype, showing higher frequency of PD-1 compared to healthy donors (HD). In addition, it was observed a decrease in the frequency of Th1-like memory CD4⁺ Treg in HCPS, important to highlight that this signature could be preserved even years after resolution of infection. Moreover, to gain insight in the mechanism involved, we evaluated whether ANDV-glycoprotein (GP) VLP could modulate CD4⁺ Treg. Interestingly, ANDV-GP VLP induced a decrease in the frequency of CXCR3 (Th1-like) and an increase in CCR4 (Th2-like) memory CD4⁺ Treg in both HD and HCPS PBMCs, indicating that ANDV-GP could specifically act over CXCR3 and CCR4 in CD4⁺ Treg. This report contributes to the study of human CD4⁺ Treg cells in ANDV infection.

1

项与 Ichor Biologics LLC 相关的新闻（医药）

2019-05-13

·BioPortfolio

Ichor Biologics is awarded $300K by the NIH to develop therapeutic antibodies to treat deadly hantavirus infections.

This article has expired, however you can still download the PDF. Preview: Ichor Biologics received a $300,000 grant from the National Institutes of Health to utilize its platform technology to develop broadly neutralizing antibodies against deadly hantavirus infections. Hantavirus infections ...

抗体

100 项与 Ichor Biologics LLC 相关的药物交易

登录后查看更多信息

100 项与 Ichor Biologics LLC 相关的转化医学

登录后查看更多信息